Dr. Reddy’s CEO Seeks To Acquire Global “String Of Pearls”
This article was originally published in PharmAsia News
Dr. Reddy's Laboratories CEO GV Prasad plans a "string of pearls," companies around the globe it can acquire to expand the firm's presence abroad. In doing so, Dr. Reddy's would leave major acquisitions to others and concentrate instead on branded drugs in the United States and generics and custom pharma services there and in other markets. The company expects the smaller acquisitions to pay off in the medium and long term. The plans are reflected in the company's announcement it would acquire BASF and its U.S. business for $40 million. (Click here for more
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.
The firm’s major product revenues bounced back from the pandemic-troubled second quarter, with Botox recovering as predicted.